Q1 Earnings Estimate for TNYA Issued By Leerink Partnrs

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Tenaya Therapeutics in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst M. Foroohar forecasts that the company will earn ($0.16) per share for the quarter. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Tenaya Therapeutics’ Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.17) EPS and FY2026 earnings at ($0.69) EPS.

Other equities analysts have also recently issued reports about the company. Canaccord Genuity Group reduced their price target on Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, March 13th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price on shares of Tenaya Therapeutics in a report on Monday. Chardan Capital decreased their price target on Tenaya Therapeutics from $18.00 to $9.00 and set a “buy” rating on the stock in a research report on Wednesday, March 12th. Finally, Morgan Stanley cut their price objective on shares of Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating for the company in a research report on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $6.25.

Tenaya Therapeutics Price Performance

Shares of TNYA stock opened at $0.57 on Wednesday. The stock has a market capitalization of $49.56 million, a price-to-earnings ratio of -0.39 and a beta of 2.83. The company’s fifty day simple moving average is $0.86 and its two-hundred day simple moving average is $1.65. Tenaya Therapeutics has a 1 year low of $0.39 and a 1 year high of $5.10.

Tenaya Therapeutics (NASDAQ:TNYA) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04.

Insiders Place Their Bets

In related news, major shareholder Group Gp Lp Column III purchased 35,714,284 shares of the business’s stock in a transaction on Wednesday, March 5th. The stock was acquired at an average price of $0.70 per share, with a total value of $24,999,998.80. Following the purchase, the insider now directly owns 49,313,559 shares in the company, valued at approximately $34,519,491.30. This represents a 262.62 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 19,621 shares of company stock worth $10,595 in the last ninety days. 32.76% of the stock is currently owned by insiders.

Institutional Trading of Tenaya Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Synovus Financial Corp bought a new position in Tenaya Therapeutics in the third quarter valued at $28,000. Woodline Partners LP purchased a new position in shares of Tenaya Therapeutics in the 4th quarter worth about $28,000. Commerce Bank bought a new position in shares of Tenaya Therapeutics during the 4th quarter valued at about $29,000. Mariner LLC purchased a new position in shares of Tenaya Therapeutics during the 4th quarter valued at about $30,000. Finally, Ground Swell Capital LLC purchased a new position in shares of Tenaya Therapeutics during the 4th quarter valued at about $32,000. Hedge funds and other institutional investors own 90.54% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.